Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Preferred Stock Liabilities (2023 - 2025)

Rein Therapeutics filings provide 3 years of Preferred Stock Liabilities readings, the most recent being $45.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $45.0 million, compared with a TTM value of $45.0 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $45.0 million, changed 0.0% over the prior year.
  • Preferred Stock Liabilities hit $45.0 million in Q4 2025 for Rein Therapeutics, roughly flat from $45.0 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $91.4 million in Q4 2023, with the low at $45.0 million in Q2 2024.
  • Median Preferred Stock Liabilities over the past 3 years was $45.0 million (2024), compared with a mean of $50.3 million.
  • The sharpest move saw Preferred Stock Liabilities plummeted 50.77% in 2024, then changed 0.0% in 2025.
  • Year by year, Preferred Stock Liabilities stood at $91.4 million in 2023, then tumbled by 50.77% to $45.0 million in 2024, then changed by 0.0% to $45.0 million in 2025.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $45.0 million, $45.0 million, and $45.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.